118 related articles for article (PubMed ID: 24714745)
1. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L; Cereda S; Aprile G; Di Girolamo S; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Vivaldi C; Belli C; Bergamo F; Lutrino SE; Filippi R; Russano M; Vaccaro V; Brunetti AE; Rotella V; Falcone A; Barbera MA; Corbelli J; Fasola G; Aglietta M; Zagonel V; Reni M; Vasile E; Brandi G
Br J Cancer; 2014 Apr; 110(9):2165-9. PubMed ID: 24714745
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
Park I; Lee JL; Ryu MH; Kim TW; Sook Lee S; Hyun Park D; Soo Lee S; Wan Seo D; Koo Lee S; Kim MH
Cancer; 2009 Sep; 115(18):4148-55. PubMed ID: 19536892
[TBL] [Abstract][Full Text] [Related]
4. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; ; ; ;
Eur J Cancer; 2019 Apr; 111():94-106. PubMed ID: 30826661
[TBL] [Abstract][Full Text] [Related]
5. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.
Li H; Zhao T; Ji X; Liang S; Wang Z; Yang Y; Yin J; Wang R
Tumour Biol; 2016 Mar; 37(3):3535-42. PubMed ID: 26453118
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
[TBL] [Abstract][Full Text] [Related]
7. Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.
Moriwaki T; Ishige K; Araki M; Yoshida S; Nishi M; Sato M; Yamada T; Yamamoto Y; Ozeki M; Ishida H; Yamaguchi T; Matsuda K; Murashita T; Abei M; Hyodo I
Med Oncol; 2014 Nov; 31(11):287. PubMed ID: 25316268
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
[TBL] [Abstract][Full Text] [Related]
9. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.
Walter T; Horgan AM; McNamara M; McKeever L; Min T; Hedley D; Serra S; Krzyzanowska MK; Chen E; Mackay H; Feld R; Moore M; Knox JJ
Eur J Cancer; 2013 Jan; 49(2):329-35. PubMed ID: 22947649
[TBL] [Abstract][Full Text] [Related]
11. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
Filippi R; Leone F; Fornaro L; Aprile G; Casadei-Gardini A; Silvestris N; Palloni A; Satolli MA; Scartozzi M; Russano M; Lutrino SE; Lombardi P; Frega G; Garattini SK; Vivaldi C; Spadi R; Giulia O; Fenocchio E; Brunetti O; Aglietta M; Brandi G
J Chemother; 2022 Apr; 34(2):123-132. PubMed ID: 34313188
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.
Thol F; Gairing SJ; Czauderna C; Thomaidis T; Gamstätter T; Huber Y; Vollmar J; Lorenz J; Michel M; Bartsch F; Müller L; Kloeckner R; Galle PR; Wörns MA; Marquardt JU; Moehler M; Weinmann A; Foerster F
JHEP Rep; 2022 Mar; 4(3):100417. PubMed ID: 35141511
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
14. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma.
Erdogan B; Turkmen E; Uzunoglu S; Tanriverdi O; Cicin I
Hepatogastroenterology; 2013 Sep; 60(126):1479-83. PubMed ID: 23933941
[TBL] [Abstract][Full Text] [Related]
15. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Saisho T; Okusaka T; Ueno H; Morizane C; Okada S
Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
[TBL] [Abstract][Full Text] [Related]
18. The impact of age and comorbidity in advanced or recurrent biliary tract cancer receiving palliative chemotherapy.
Takahara N; Nakai Y; Saito K; Sasaki T; Suzuki Y; Inokuma A; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Isayama H; Koike K
J Gastroenterol Hepatol; 2020 Oct; 35(10):1828-1835. PubMed ID: 32267557
[TBL] [Abstract][Full Text] [Related]
19. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
